![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
References
- Levin A. Identification of patients and risk factors in chronic kidney disease - evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant 2001;16:57-60
- National Kidney Foundation -- Dialysis Outcomes Quality Initiative. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37:182-238
- Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999;14:1-50
- Locatelli F, Aljama P, Bárány P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19:1-47
- Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-8
- Winearls CG, Oliver DO, Pippard MJ, et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;2:1175-8
- Tjulandin SA, Bias P, Elsässer R, et al. Epoetin theta in anaemic cancer patients receiving platinum-based chemotherapy. Arch Drug Info 2010;3;45-53
- Tjulandin SA, Bias P, Elsässer R, et al. Epoetin theta with a new dosing schedule in anaemic cancer patients receiving nonplatinum-based chemotherapy. Arch Drug Info 2011;4;33-41
- Gertz B, Kohler E, Kes P, et al. Epoetin theta: efficacy and safety of IV administration in anaemic haemodialysis patients in the maintenance phase in comparison to epoetin beta. Curr Med Res Opin 2010;26:2393-402
- FDA: Darbepoetin alfa, Summary Basis of Approval, 2001
- Hörl WH, Holzer H, Mayer GJ. Treatment of renal anaemia with darbepoetin alfa -- Results of an Austrian multicentre study. Wien Klin Wochenschr 2002;114:967-71. German
- EMA, Epoetin beta, Summary of Product Characteristics, revised 11 May 2010
- Provenzano R, Bhaduri S, Singh AK for the PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol 2005;64:113-23
- Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Eng J Med 2006;335:2071-84
- Provenzano R, Garcia-Mayol L, Suchinda P, et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 2004;61:392-405
- Hoggard J, Crouch T, McMurray S, et al. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis. Cur Med Res Opin 2006;22:2023-30
- Wizemann V, Rutkowski B, Baldamus C, et al. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Cur Med Res Opin 2008;24:625-37
- Haag-Weber M, Vetter A, Thyroff-Friesinger U, et al. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving haemodialysis. Clin Nephrol 2009;72:380-90
- Haag-Weber M, Eckhardt K-U, Hörl WH, et al. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia. Clin Nephrol 2012;77:8-17